Autopsy report · NCT00899353
Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
Cause of deathStaffing, sites or logistics
“Original Principal Investigator left the institution.”
Life of this trial
- Registered 9 months after it had already started.
- Ran for about 4 years 2 months before it stopped.
- 16 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Marshall University
- Sponsor type
- University, hospital or other
- Conditions
- Monoclonal Gammopathy of Undetermined Significance; Smoldering Multiple Myeloma; Chronic Lymphocytic Leukemia
- Interventions
- Omega 3 Fatty Acid
- Participants
- 16
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma
“The original principal Investigator left the institution.” - Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
“Principal investigator left the institution.” - Detailed Clinical, Biochemical and Genetic Characterization in Gonadotropin-releasing Hormone (GnRH) Deficiency Disorders
“the Principal Investigator left the institution” - Identification and Characterization of Molecular Markers in Musculoskeletal Tumors
“Principal Investigator has left the Institution” - Incisional Hernia Outcomes Study Using Parietex Composite Mesh
“Principal Investigator left institution.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.